tbuckley/cabot-search huggingface dataset:
Clinical controlled study of acupuncture and movement therapy for treatment of fasciitis of lumber muscles
Authors: Dong-mei Liu
Journal: BMJ (2009)

One hundred and fifty-two cases of fasciitis of lumber muscles were divided into two groups.The treatment group of 75 cares war treated with acupuncture and movement therapy bared on syndrome differentiation with meridians and collaterals using points of Shuigou(DU26)or Houxi(S13),Shousanli(LI10)or Tmchong(LR3);while 77 cages in the control group were treated with simple acupuncture and Ashi points and Weizhong(BL40).The total efficacy rate Wag 86.7%in the treatment group and 64.9%in the control group(P＜0.01).The effect of immediate pain relief in treatment group WaR better than that of the control group,with the VAS scores significantly decreased(P＜0.01).Acupuncture and movement therapy is effective for treatment of fasciitis of lumbar muscles.

Key words: 
Myofascial pain syndromes;  Acupuncture-moxibustion
偏头痛与缺血性脑血管病
Authors: 刘若卓, 于生元
Journal: BMJ (2010)

偏头痛是临床上反复或周期性发作的神经-血管功能障碍性头痛,是以单侧或双侧搏动性头痛伴有或不伴有视觉先兆为主的一类疾病,常伴恶心、呕吐、畏光、倦怠、抑郁;但其作为一种功能致残性疾病,长期以来被认为并不影响患者预后.然而,近年来研究发现偏头痛与脑梗死关系十分密切。
社区卫生服务在烧伤救治中作用初探
Authors: 唐祖国, 梅琳
Journal: BMJ (2010)

只有社区卫生有序发展,综合服务能力提高,才会在烧伤救治中发挥更多、更大作用.现对我院在2008年9月至2009年7月与对口的社区卫生服务中心实施双向转诊的51例烧伤患者临床资料进行分析,探讨社区医疗在烧伤救治中的作用。
Understanding therapy preferences of cancer patients with the use of therapy preference scale.
Authors: Prajwal Dhakal, Christopher S Wichman, Bunny J Pozehl, Julie Vose, Gregory Bociek, Vijaya Raj Bhatt
Journal: Journal of Clinical Oncology (2020)

e24186 Background: Patients’ (pts) preferences, crucial in selecting an appropriate treatment (tx), are understudied in cancer pts. We developed a novel self-reported questionnaire “Therapy Preference Scale” (TPS) (J Geriatr Oncol. 2019:677-679, J Clin Oncol 2019 37: e23179-e23179). Our single-center prospective observational study utilized TPS to gain in-depth understanding of pts’ preferences of various aspects of cancer tx. Methods: Eligible pts were adults aged ≥19 y with a diagnosis of cancer. Pts were asked to complete TPS; this 30-item scale captures pts’ rating of the importance of safety, efficacy and other characteristics of cancer tx (on a scale of 0-10), and importance of one over the other aspects of tx (using a 4-item Likert scale). Demographics, cancer-specific and therapy-related data were collected. Descriptive statistics were used for analysis. Results: Total 100 pts were enrolled- 52% were receiving cancer tx; 40% had completed tx; 8% were newly diagnosed and had not yet started tx. Pts were willing to accept short term SE for increased life expectancy but valued maintenance of cognition, functional ability and QoL. 70% valued maintaining cognition, functional ability and quality of life (QoL) than increased life expectancy; 75% would accept cancer tx if it improved QoL but 88% would reject a harsh tx for improved life expectancy of ≤6 months. Conclusions: Avoiding long term side effects (SE), life threatening infections, tx burden and financial toxicity were most important to pts. Harsh tx with ≤6 months improvement of life was unacceptable. These findings will help physicians understand pt preferences and guide selection of tx that will meet pts’ goals of care, and may also have implications for insurance policies and drug approval. [Table: see text]
Application of MammaPrint test on Chinese patient with breast cancer.
Authors: Chen Tian, Lili Fu, Jiyu Wei, Pengfei Yin, Henghui Zhang
Journal: Journal of Clinical Oncology (2020)

e13671 Background: A 70-gene prognosis-signature, known as MammaPrint (MP), is validated as a good predictor of recurrence in patients with ER+/HER2- early stage breast cancer in Europe and America. Previous studies on Japanese and Korean breast cancer patients showed that the proportion of MP Low-Risk tumours is significantly lower than the percentage which reported in previous studies. Here we use MammaPrint to determine the gene profiles of breast cancer tumours from Chinese patients and investigate the test’s potential clinical applications. Methods: Formalin-fixed, paraffin-embedded (FFPE) tumour samples or fresh tumour samples from 594 eligible breast cancer patients were collected from 97 hospitals in China. Tumor RNAs were isolated from samples and analyzed using RNA sequencing technology. Clinical risk was categorized based on the Adjuvant! algorithm as used in the MINDACT trial. Concordance between risk predicted by the MammaPrint and clinical characteristics were evaluated. We also analyzed the clinical-pathology features of patients and compared them to previous studies. Results: Overall, 315 patients were categorized as clinical high risk (182 were MP Low-Risk and 133 MP High-Risk), while 279 patients were categorized as clinical low risk (203 were MP Low-Risk and 76 MP High-Risk). The concordance rate between risk predicted by the MammaPrint and clinical characteristics was 56.57%. Among the clinical-pathology features, age, ER/PR/HER2 status, tumour grade and tumour size were significantly related to the genomic risk (p = 0.009, 0.003, &lt; 0.001, 0.001, &lt; 0.001, and 0.007 respectively). Conclusions: The proportion of MP Low-Risk tumours was 64.81%, which is similar to previous validated studies in Europe and America. Of the patients that were clinical high risk, 58% was categorized as MP Low-Risk, and this group of patients may have limited benefit from chemotherapy. Our results indicate that MammaPrint is applicable to Chinese patients and has potential value in clinical practice to avoid over-treatment.
Genome-wide CRISPR/Cas9 library screening to identify PAK1 as a critical driver for lenvatinib resistance in HCC.
Authors: Shanzhou Huang, Chuanzhao Zhang, Baohua Hou
Journal: Journal of Clinical Oncology (2020)

e16687 Background: Lenvatinib demonstrated noninferiority to sorafenib in overall survival and a statistically significant increase in progression-free survival in patients with unresectable hepatocellular carcinoma (HCC). However, the development of drug resistance of lenvatinib is becoming common. Methods: Here, we performed the first genome-wide CRISPR/Cas9-based screening on lenvatinib-treated HCC cells to identify essential genes for non-mutational mechanisms related to acquired lenvatinib resistance and/or sensitivity in HCC cells. A genome-scale CRISPR knockout (mGeCKOa) library containing 123,411 single guide RNAs (sgRNAs) was used to identify loss-of-function mutations conferring lenvatinib resistance upon HCC cells. CCK8, wound-healing, transwell and flow cytometry assays were used. Subcutaneous xenotransplantation models were used to investigate the role in vivo. Results: By using genome-wide CRISPR/Cas9 library screening, we identify PAK1, a family member of serine/threonine p21-activating kinases, as a critical driver for lenvatinib resistance and the most-effective genetic suppressor of lenvatinib activity. Analysis of the survival of HCC after hepatic resection revealed that low PAK1 expression shortened overall and tumor-free survival (P &lt; 0.001). Further, loss of PAK1 from HCC cell increased the cytotoxicity of lenvatinib in vivo. Lenvatinib treatment activates series of metabolism, including “Glycolysis/ Gluconeogenesis、Cysteine and methionine metabolism、Selenocompound metabolism、Sphingolipid metabolism、Pyruvate metabolism、Metabolic pathways”. With RNAi knockdown and CRISPR/Cas9 knockout models, we show that loss of PAK1 activates the Glycolysis/ Gluconeogenesis and increase the production related metabolites. Concomitantly, activation of PAK1 reduces ROS level and HCC apoptosis upon Lenvatinib treatment. Lenvatinib treatment activates series of metabolism, including “Glycolysis/ Gluconeogenesis”. With RNAi knockdown and CRISPR/Cas9 knockout models, we show that loss of PAK1 activates the Glycolysis/ Gluconeogenesis and increase the production related metabolites. Concomitantly, activation of PAK1 reduces ROS level and HCC apoptosis upon Lenvatinib treatment. Conclusions: In summary, our results demonstrate that targeting PAK1 is an effective approach to overcome lenvatinib drug resistance in HCC.
TRIM24 promotes stemness and invasiveness of glioblastoma cells via activating Sox2 expression
Authors: Lu-hua Zhang, Yi-heng Yin, Hong-zun Chen, Shi-yu Feng, Jia-lin Liu, Ling Chen, Wen-liang Fu, Guo-chen Sun, Xin-guang Yu, Dong-gang Xu
Journal: Neuro-Oncology (2020)

Abstract Background Glioblastoma stem cells (GSCs) are a subpopulation of glioblastoma (GBM) cells that are critical for tumor invasion and treatment resistance. However, little is known about the function and mechanism of tripartite motif-containing 24 (TRIM24) in GSCs. Methods Immunofluorescence, flow cytometry, and western blot analyses were used to evaluate TRIM24 and cluster of differentiation (CD)133 expression profiles in GBM surgical specimens and GSC tumorspheres. Different TRIM24 expression levels in patients’ tumors, as measured by both immunohistochemistry and western blot, were related to their corresponding MRI data. Wound healing, Matrigel invasion, and xenograft immunohistochemistry were conducted to determine GBM cell invasion. Results We identified that TRIM24 was coexpressed with CD133 and Nestin in GBM tissues and tumorsphere cells. Limiting dilution assays and xenotransplantation experiments illustrated that knockdown of TRIM24 expression reduced GSC self-renewal capacity and invasive growth. TRIM24 expression levels were positively associated with the volumes of peritumoral T2 weighted image abnormality. Rescue experiments indicated TRIM24 participation in GBM infiltrative dissemination. Chromatin immunoprecipitation, reporter gene assay, PCR, western blot, and immunohistochemistry demonstrated that TRIM24 activated the expression of the pluripotency transcription factor sex determining region Y–box 2 (Sox2) to regulate GBM stemness and invasion in vitro and in vivo. Finally, the close relationship between TRIM24 and Sox2 was validated by testing samples enrolled in our study and exploring external databases. Conclusions Our findings uncover essential roles of the TRIM24–Sox2 axis in GBM stemness and invasiveness, suggesting TRIM24 as a potential target for effective GBM management.
Evaluation of combined BCL-2/MCL-1 inhibition as a therapeutic approach for synovial sarcoma.
Authors: Carter Kent Fairchild, Konstantinos Floros, Sheeba Jacob, Colin Coon, Madhavi Puchalapalli, Bin Hu, Mikhail Dozmorov, Jennifer Koblinski, Steven Smith, Gregory Domson, Hiromichi Ebi, Anthony Faber, Sosipatros Alexandros Boikos
Journal: Journal of Clinical Oncology (2020)

e23561 Background: While Synovial Sarcoma (SS) only accounts for about 10% of soft tissue sarcomas (STS), or ~10,000 cases/year, ~4,000 of these will be fatal. Little benefit has been seen with newer combination chemotherapies and immune checkpoint inhibitors. SS is a transcription factor-driven cancer characterized by an t(X;18) chromosomal translocation resulting in the SS18-SSX fusion gene. SS is also known to overexpress the anti-apoptotic protein BCL-2, which has been used as a diagnostic marker for SS. Venetoclax, the FDA approved BH3 mimetic which specifically inhibits BCL-2, has been used to treat BCL-2-driven hematological cancers. Yet, preclinical studies of venetoclax, currently in clinical use for BCL-2 related hematologic malignancies, have failed in SS, raising the possibility of other BCL-2 family members playing a role in resistance. Methods: Publicly available gene expression databases of SS were queried for expression of BCL-2 family member expression, including the endogenous MCL-1 inhibitor, NOXA. Six SS cell lines, including ASKA, HS-SY-II, Yamato, SW982, SYO.1, and an ex vivo line from a SS patient-derived xenograft (PDX) were tested in vitro with combinations of venetoclax and the MCL-1 inhibitor S63845, using cell viability assays. In vivo testing employed both a patient-derived xenograft (PDX) model of SS and a cell line derived (SYO.1) xenograft model. Results: Queries of published gene expression data for SS demonstrated that SS expresses low levels of the endogenous MCL-1 inhibitor, NOXA, nominating a mechanism for intrinsic venetoclax resistance in these tumors, and suggesting rational combination of venetoclax and the MCL-1 inhibitor, S63845. In vitro, SS all cell lines possessing the SS18-SSX fusion gene demonstrated synergistic sensitivity to combined S63845 and venetoclax, despite generally insensitivity to either drug as monotherapy. Importantly, in an SS PDX, we demonstrated S63845 and venetoclax synergize to induce tumor regression. In the SYO.1 xenograft model, combination therapy significantly reduced tumor growth compared to no treatment or single agent groups. Conclusions: These findings provide the preclinical rationale for translation of the rational combination of BCL-2 and MCL-1 inhibitors into clinical trials for SS.
Circulating tumor DNA (ctDNA) analysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.
Authors: Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi Wu
Journal: Journal of Clinical Oncology (2020)

9023 Background: Circulating tumor DNA can be detected in the plasma and serum of patients with solid tumors and has emerged as a noninvasive biomarker for dynamically monitoring tumor. Postsurgical ctDNA analysis of early-stage NSCLC may identify patients at high risk of recurrence and facilitate early intervention and personalized cancer therapy. Methods: These studies recruited 123 patients with newly diagnosed resectable stage I-IIIA NSCLC. Preoperative and postoperative plasma and postoperative tissue samples were subjected to next-generation sequencing (Nanjing Shihe Jiyin Biotechnology Inc.) using a 425 cancer-related genes panel. Peripheral blood samples were collected before surgery, postoperatively within 1 month, and every 3-6 months for up to 3 years. Plasma samples with at least 1 variants detected in tissue samples were defined as ctDNA positive. Results: After 4 exclusions, 119 eligible patients were enrolled from June 2016 to February 2019. Presurgical ctDNA was detectable in 31 of 117 (26.5%) patients and was associated with inferior recurrence-free survival (HR, 3.90, 95% CI, 1.44-10.58, P = 0.004). Similarly, ctDNA was detected in 13 of 116 (11.2%) of the first postsurgical samples and was associated with shorter RFS (HR, 3.54, 95% CI, 1.22-10.23, P = 0.002). During surveillance after surgery, ctDNA-positive patients (38/119, 31.9%) were more than 9 times more likely to experience disease recurrence than ctDNA-negative patients (HR, 9.17, 95% CI, 2.60-32.42, P &lt;0.001). Serial ctDNA detection preceded radiologic disease recurrence by a median lead time of 4.23 months (95% CI, 0.91-7.54 months). We also observed a positive correlation between the ctDNA detection rate and the disease stage. Conclusions: These results suggest that detection of ctDNA before and after surgery is associated with the identification of a high risk of disease recurrence of resectable NSCLC. Perioperative ctDNA analyses identify disease recurrence earlier than standard-of-care radiologic imaging, and thus could facilitate personalized cancer treatment at early time points. Clinical trial information: NCT03465241 and NCT03172156.
Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight
Authors: Chunting He, Ming Qin, Xun Sun
Journal: Acta Pharmaceutica Sinica B (2020)

Coronaviruses (CoVs) are a large family of viruses that cause illness ranging from the common cold to more severe diseases such as Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) has caused major public health crises. There have been more than 4,400,000 reported cases of COVID-2019 and more than 300,000 reported deaths to date (16/05/2020). SARS-CoV, MERS-CoV and SARS-CoV-2 have attracted widespread global attention due to their high infectivity and pathogenicity. To date, there is no specific treatment proven effective against these viral infectious diseases. Vaccination is considered one of the most effective strategies to prevent viral infections. Therefore, the development of effective vaccines against highly pathogenic coronaviruses is essential. In this review, we will briefly describe coronavirus vaccine design targets, summarize recent advances in the development of coronavirus vaccines, and highlight current adjuvants for improving the efficacy of coronavirus vaccines.
红药膏治疗尿布皮炎50例疗效观察
Authors: 汪宝凤, 刘燕
Journal: BMJ (2005)

为了观察红药膏治疗尿布皮炎的疗效,将1998年至2003年门诊初诊患尿布皮炎的100例患儿随机分成治疗组和对照组各50例,治疗组用红药膏,对照组用氧化锌油,治疗尿布皮炎并对疗效进行分析.结果显示治疗组痊愈30例(60%),显效15例(30%),好转5例(10%);对照组痊愈11例(22%),显效14例(28%),有效16例(32%),无效9例(18%).可见红药膏治疗尿布皮炎的疗效优于氧化锌油(P＜0.01)。
Microsatellite instability and KRAS mutation in stage 4 CRC: Prevalence, geographic discrepancies and outcomes from the National Cancer Database.
Authors: Johannes Uhlig, Michael Cecchini, Stacey Stein, Jill Lacy, Kevin Kim
Journal: Journal of Clinical Oncology (2020)

e16052 Background: To assess microsatellite instability (MSI) and KRAS mutation prevalence, discrepancies and their impact on outcome in AJCC stage IV colorectal adenocarcinoma (colorectal cancer; CRC). Methods: The 2010-2016 United States National Cancer Database was queried for stage IV CRC patients &gt; 18yo and information on MSI and KRAS mutation. Microsatellite status was stratified as stable microsatellites (MSS, including low instability) and microsatellite instability high (MSI-H). KRAS status was stratified as mutation and wildtype. Prevalence and discrepancies were evaluated according to patient demographics, US geography and CRC factors. Overall survival (OS) was assessed using Cox proportional hazards models adjusting for age, gender, race, comorbidities, metastatic burden, CRC treatment, treatment center type, and year of CRC diagnosis. A priori, a statistical interaction test between microsatellite status, KRAS status and primary CRC site was planned. Results: Microsatellite/KRAS status was available for n = 10,844/n = 25,712 patients, respectively. OS was assessed in n = 5,904 patients with data on both microsatellite and KRAS status, and follow-up. Overall prevalence of MSI-H was 3.1% and KRAS mutation 42.4%. Microsatellite and KRAS status varied according to primary CR site, as presented in Table. Further variation was evident according to US-geography, with MSI-H rates ranging from 1.6% to 4.1%, and KRAS mutation rates ranging from 41.1% to 44%. On multivariable analyses, longer OS was observed in patients with KRAS wildtype versus mutation (HR = 0.91, 95% CI: 0.85-0.97 p = 0.004), MSS versus MSI-H (HR = 0.75, 95% CI: 0.62-0.9, p = 0.003), and left-sided versus right-sided CRC (HR = 0.65, 95% CI: 0.6-0.7, p &lt; 0.001). The effect of KRAS mutation further varied with CRC site and microsatellite status (interaction p = 0.002). Conclusions: Depending on its primary site and US geography, stage IV CRC shows distinct mutational behavior. KRAS mutation, MSI-H, MSI-H and primary CRC sidedness independently affect overall survival and interact with distinct prognostic profiles. Generically classifying adenocarcinomas of different site as “CRC” might deprecate this diversity. [Table: see text]
Retroperitoneal iaparoscopic ureterolithotomy for impacted upper-ureteral calculi: a report of 42 cases
Authors: Yun-yan Wang, Jun-song Meng, Yong Wang, Zong-yuan Xu, Pei-jin Hou, Haijun Zhuang, Peng Tang
Journal: BMJ (2012)

The clinical data of 42 patients with impacted upper-ureteral calculi undergoing retroperitoneal laparoscopic ureterolithotomy (RPLU) from January 2008 to December 2010 were retrospectively analyzed.RPLU was successfully performed in 40 cases,and simultaneous laparoscopic electrocoagulation ablation was also performed in 11 cases complicated with ureteral inflammatory polyps.No massive bleeding occurred during the operations.The stone-free rate 3 d after operation was 100％,and no stone left as reviewed by kidney ureter bladder X-ray (KUB) and B-ultrasonography.During the follow-up of 3 to 24 months (mean 11 months),40 cases showed no stone recurrence and no ureteral stricture in KUB and B-ultrasonography.The hydronephrosis of all RPLU patients relieved.Results indicate that RPLU is a safe and effective minimally invasive operation for treatment of impacted upper-ureteral calculi.

Key words: 
Laparoscopy;  Ureteral calculi
EAACI Biologicals Guidelines—Recommendations for severe asthma
Authors: Ioana Agache, Cezmi A. Akdis, Mubeccel Akdis, Giorgio Walter Canonica, Thomas Casale, Tomas Chivato, Jonathan Corren, Derek K. Chu, Stefano Del Giacco, Thomas Eiwegger, Breda Flood, Davide Firinu, James E. Gern, Eckard Hamelmann, Nicola Hanania, Irene Hernández‐Martín, Rebeca Knibb, Mika Mäkelä, Parameswaran Nair, Liam O’Mahony, Nikolaos G. Papadopoulos, Alberto Papi, Hae‐Sim Park, Luis Pérez de Llano, Oliver Pfaar, Santiago Quirce, Joaquin Sastre, Mohamed Shamji, Jurgen Schwarze, Oscar Palomares, Marek Jutel
Journal: Allergy (2020)

Abstract Severe asthma imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co‐morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of severe asthma, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include selection of a certain biological (as they all target overlapping disease phenotypes), the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home‐based) and its cost‐effectiveness. The EAACI Guidelines on the use of biologicals in severe asthma follow the GRADE approach in formulating recommendations for each biological and each outcome. In addition, a management algorithm for the use of biologicals in the clinic is proposed, together with future approaches and research priorities.
Diagnosis and treatment of adrenocorticotropic hormone-independent macronodular adrenocortical hyperplasia
Authors: Jiang Li, Li-ming Li
Journal: BMJ (2012)

Twelve cases of adrenocorticotropic hormone-independent macronodular adrenocortical hyperplasia were retrospectively reviewed.All cases had physical signs and biochemical evidence of Cushing syndrome. Urinary free cortisone (UFC) levels were not suppressed by high dose and low dose dexanethasone suppression tests,and plasma adrenocorticotropic hormone levels were low in all patients.CT scan showed bilateral enlarged adrenal glands in all cases,and histopathologic examination confirmed bilateral adrenal macronodular hyperplasia. The follow-up revealed that 4 patients had a normal blood pressure 8y after bilateral adrenalectomy. In 8 cases the blood pressure was rebound 3y after single side adrenalectomy,6 of whom had medical treatment; 2 of whom had contralateral adrenalectomy and the blood pressure returned to normal afterwards.There was no Nelson syndrome in all cases.

Key words: 
Adrenal cortex diseases; Cushing syndrome
Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes
Authors: Snorgaard Ole, Poulsen Grith M, Andersen Henning K, Astrup Arne, 黄融, 范竹萍
Journal: BMJ (2017)

目的
营养治疗是2型糖尿病患者自我管理教育的一个组成部分，推荐摄入升糖指数低的碳水化合物，但对于饮食中碳水化合物的理想含量还不清楚。我们进行了一项荟萃（meta）分析，在2型糖尿病患者中比较了低-中等含量碳水化合物饮食（LCD）（能量百分比低于45%）和高碳水化合物饮食（HCD）的区别。


方法
我们系统回顾了Cochrane数据库、EMBASE和MEDLINE在2004—2014年期间的指南、meta分析和随机对照试验，评估HbA1c、体质指数（BMI）、体质量、低密度脂蛋白胆固醇和生活质量（QoL）。


结果
确定了10个随机试验，共有1 376名参与者。在干预的第一年，相较于HCD组，LCD组HbA1c降低0.34%（3.7 mmol/mol）。碳水化合物限制越严格，血糖降低也更明显（R=-0.85，P<0.01）。然而在1年以后，2个饮食组的HbA1c水平相似。2种饮食对BMI/体质量、低密度脂蛋白胆固醇和生活质量的影响在整个干预过程中都是相似的。


局限性
降糖药物、营养治疗、饮食中碳水化合物的含量、升糖指数、脂肪和蛋白质的摄入量、HbA1c基线水平以及是否能够坚持规定饮食都可能影响结果。


结论
LCD在第一年内对2型糖尿病患者血糖控制的影响比HCD者更大。该研究首次发现碳水化合物的限制越严格，降糖效果越明显。除了短期内降低HbA1c的作用之外，低含量碳水化合物饮食在血糖控制、降低体重或降低低密度脂蛋白胆固醇方面没有优势。